Tempest Therapeutics Inc (TPST)

08:32 AM

Tempest Therapeutics Showcases Strong TPST-2003 CAR-T Data - TipRanks

08:32 AM

07:45 AM

TPST-2003 delivers 100% CRs in rrMM, Tempest (NASDAQ: TPST) says - Stock Titan

07:45 AM

07:00 AM

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting - Yahoo! Finance Canada

07:00 AM

May 05, 2026

MSN Money - MSN

May 05, 2026

Apr 30, 2026

TPST Q1'26 Earnings: revenue estimate is 0 USD - TradingView

Apr 30, 2026

Apr 29, 2026

After six complete responses, Tempest brings updated CAR-T data to Dublin - Stock Titan

Apr 29, 2026

Apr 29, 2026

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting - Sahm

Apr 29, 2026

Apr 25, 2026

TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction - MSN

Apr 25, 2026

Apr 24, 2026

Tempest Therapeutics stock falls after $4.25 million direct offering - MSN

Apr 24, 2026

Apr 23, 2026

Tempest achieves manufacturing milestone for CAR-T therapy By Investing.com - Investing.com India

Apr 23, 2026

Apr 22, 2026

Tempest Therapeutics provides update on development of TPST-2003 - TipRanks

Apr 22, 2026

Apr 22, 2026

Tempest Therapeutics (TPST) Advances Dual-Targeting CAR-T Therap - GuruFocus

Apr 22, 2026

Apr 22, 2026

Tempest achieves manufacturing milestone for CAR-T therapy - Investing.com

Apr 22, 2026

Apr 22, 2026

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T - GlobeNewswire

Apr 22, 2026

Apr 20, 2026

Tempest Therapeutics (TPST) Stock: Why Spinoff Value (Tick Down) 2026-04-20Trending Buy Opportunities - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026

Apr 17, 2026

TPST Forecast, Price Target & Analyst Ratings | TEMPEST THERAPEUTICS INC (NASDAQ:TPST) - ChartMill

Apr 17, 2026

Apr 15, 2026

Tempest Therapeutics names Andrew Fang head of business development By Investing.com - Investing.com India

Apr 15, 2026

Apr 14, 2026

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts - Bitget

Apr 14, 2026

Apr 14, 2026

Tempest Therapeutics names Andrew Fang head of business development - Investing.com

Apr 14, 2026

Apr 14, 2026

Tempest Appoints Andrew Fang, Ph.D., as Head of Business - GlobeNewswire

Apr 14, 2026

Apr 13, 2026

Tempest Therapeutics(TPST) Stock Options Chain | Quotes & News - Moomoo

Apr 13, 2026

Apr 12, 2026

Form S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments - ADVFN

Apr 12, 2026

Apr 10, 2026

Tempest Therapeutics (NASDAQ: TPST) registers 2.78M resale shares from private placement - Stock Titan

Apr 10, 2026

Apr 10, 2026

Tempest Therapeutics (NASDAQ: TPST) registers 8.27M shares for resale by sellers - Stock Titan

Apr 10, 2026

Apr 10, 2026

Buyout Rumor: What is Stran Company Incs revenue forecast2026 Technical Patterns & Weekly Breakout Stock Alerts - baoquankhu1.vn

Apr 10, 2026

Apr 10, 2026

New Strong Buy Stocks for April 10th - The Globe and Mail

Apr 10, 2026

Apr 10, 2026

Can Tempest Therapeutics (TPST) Stock Maintain Growth | Price at $1.79, Up 13.29%Community Chart Signals - Cổng thông tin điện tử Tỉnh Sơn La

Apr 10, 2026

Apr 10, 2026

[EFFECT] Tempest Therapeutics, Inc. SEC Filing - Stock Titan

Apr 10, 2026

Apr 03, 2026

Tempest Therapeutics, Inc. announced that it has received $1.999539 million in funding from Factor Bioscience Inc. and other investors - marketscreener.com

Apr 03, 2026

Apr 02, 2026

Tempest Therapeutics (TPST) grants 22,000 stock options to Corporate Controller - Stock Titan

Apr 02, 2026

Apr 02, 2026

Tempest Therapeutics (TPST) CFO receives 140,000 stock options at $1.64 - Stock Titan

Apr 02, 2026

Apr 02, 2026

Versant funds report lower Tempest Therapeutics (TPST) ownership levels - Stock Titan

Apr 02, 2026

Apr 02, 2026

Biopharmaceutical company Tempest Therapeutics Inc (TPST) recently filed a prospectus with the U.S. Securities and Exchange Commission, planning to issue up to approximately 2.8 million common shares through resale, including related warrants. - Bitget

Apr 02, 2026

Apr 02, 2026

According to a filing submitted to the US Securities and Exchange Commission (SEC), Tempest Therapeutics Inc. will not receive any proceeds from the sale of the company's shares by selling shareholders. - Bitget

Apr 02, 2026

Apr 01, 2026

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Tempest Therapeutics (TPST) - The Globe and Mail

Apr 01, 2026

Apr 01, 2026

Tempest Therapeutics | UPLOAD: Others - Moomoo

Apr 01, 2026

Mar 31, 2026

H.C. Wainwright Maintains Tempest Therapeutics(TPST.US) With Buy Rating, Maintains Target Price $11 - moomoo.com

Mar 31, 2026

Mar 31, 2026

TPST Q4'25 Earnings: EPS estimate is (0.62) USD - TradingView — Track All Markets

Mar 31, 2026

Mar 30, 2026

According to the latest filing disclosed by the SEC, existing shareholders of biopharmaceutical company Tempest Therapeutics Inc. plan to resell up to 8.27 million shares of the company's common stock. - Bitget

Mar 30, 2026

Mar 30, 2026

Scienture Holdings Inc (MEDS) Reports FY2025 Earnings - AlphaStreet

Mar 30, 2026

Mar 30, 2026

Tempest Reports Year End 2025 Financial Results and Provides Business Update - bitget.com

Mar 30, 2026

Mar 30, 2026

Tempest reports year end 2025 financial results and provides business update - marketscreener.com

Mar 30, 2026

Mar 30, 2026

Tempest Therapeutics, Inc. (TPST) Reports FY2025 Earnings - AlphaStreet

Mar 30, 2026